# DESTINY-Lung01 (NCT03505710)

> DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03505710
- Phase: PHASE2
- Status: TERMINATED
- Sponsor: Daiichi Sankyo
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Trastuzumab deruxtecan
- Enrollment: 181
- Primary outcome: Percentage of Participants With Objective Response Rate (ORR) Based on Independent Central Review Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)

## Commentary we found

- Podcasts: 69
- YouTube: 33
- X threads: 22
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=destiny-lung01-nct03505710

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03505710", "email": "<work email>"}; the inbox owner confirms by the emailed link.